Global Pharmaceutical & Biotechnology Outlook 2013: India Pharma


Naperville, IL -- (SBWIRE) -- 03/19/2014 -- Reportstack, provider of premium market research reports announces the addition of Global Pharmaceutical & Biotechnology Outlook 2013: India Pharma market report to its offering
India pharma rode on the wave of bunched up patent expiries in the US with many Para IV launches in 2012. In addition, it also benefited from the continuing high teen growth of Indian pharma market.  With patent expiries in the US dwindling from $30b in 2012 to $10b in 2013 (small molecules), Indian generic companies will now need to focus on complex generics that offer sustainability of earnings.  Locally acting drugs and targeted drug delivery products make up for the bulk of complex formulation generics.  We have analyzed this space and have provided a fairly comprehensive list of products falling under these categories indicating that topical drugs remains the most near term opportunity for generics.  Inhalers offer the most lucrative opportunity, though not before 2016.

Our growth outlook on Indian market continues to remain optimistic with 15-18% growth.  This is based on the silent reforms in India that started with implementation of a strict GMP (Good Manufacturing Practices) in 2005, continued with implementation of GLP (Good Laboratories Practices) in 2011 and now the bar coding norms at primary and secondary levels. All these continue to put pressure on the very small manufacturer ultimately leading to industry consolidation – something that augurs well for world’s most fragmented pharma market.  We do not see any negative impact due to the newly announced National Pharma Pricing Policy (NPPP) due to its emphasis on market price based pricing policy.  

Our top pick remains Sun Pharma as it remains the best positioned to tide over the patent cliff with its latest acquisitions, DUSA and URL Pharma. A strong balance sheet further allows it to acquire more such high value targets. We also recommend Natco Pharma for its focus on complex generics like Copaxone, Revlimid and Tamiflu. Besides this, its domestic market strategy targeted at gaining Compulsory License on high value oncology products too remains lucrative.

Key Topics Covered

Complex Formulations – Scope and Opportunity in US market

Liposomal Drugs: Opportunities for Generic Companies

Colon Targeted Drugs: Opportunities for Generic Companies

Transdermal Drugs: Opportunities for Generic Companies

Topical Dermatological Drugs: Opportunities for Generic Companies

Inhalers: Opportunities for Generic Companies

Reforms and Consolidation Continues in Domestic Market

New Pharma Pricing Policy – Neutral to Positive for the Industry

IPCA: Momentum Continues

Natco: Entering the Big League Through Multi Pronged Strategy

Sun Pharma: Balance Sheet Leveraging at Play

Aurobindo: Still Not Out of the Woods

Dishman: Management Accepts The Limitations of Pure Play Crams

Biocon: Expenses More Visible than Growth Drivers

Cadila Healthcare: In a Phase of Consolidation

Cipla: Weakness in Regulated Markets Persists

Dr Reddy’s Lab: Moderate Earnings Due to High Base and Upfront Investment

Lupin: Margin Worry on Base Business

Ranbaxy: Improvement in Base Business Margin is Still Uncertain

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604